Bipolar Disorder Market Summary
The Bipolar Disorder market across the seven major markets (7MM) is anticipated to expand significantly during the forecast period 2026–2036, supported by increasing diagnosis, greater mental health awareness, evolving treatment approaches, and continued development of innovative therapies. According to DelveInsight, the Bipolar Depression market is expected to grow at a significant CAGR from 2022 to 2036. In 2023, the United States represented the largest share of the 7MM market, with a market size of approximately USD 2,300 million, followed by Germany and Italy. The US accounted for around 85% of the overall Bipolar Depression market among the 7MM.
The treatment landscape is increasingly focused on addressing the depressive phase of bipolar disorder, which represents a major area of unmet medical need. Existing therapies include antipsychotics and mood-stabilizing treatments, while newer candidates are being investigated to provide faster symptom relief, improved tolerability, and more targeted mechanisms of action. By 2036, CAPLYTA (lumateperone) is projected to achieve the largest market share among currently available therapies, while emerging candidates such as NRX-100 and NRX-101 are expected to gain meaningful market penetration.
Explore DelveInsight’s Full Coverage on the Bipolar Disorder Market
Bipolar Disorder Overview
Bipolar Disorder, historically referred to as manic depression or manic depressive illness, is a chronic mental health condition characterized by substantial changes in mood, energy, activity, concentration, and daily functioning. The condition can involve depressive episodes, manic episodes, hypomania, mixed features, and rapid cycling. Major classifications include Bipolar I Disorder, Bipolar II Disorder, cyclothymic disorder, and other specified forms.
Bipolar depression represents a particularly important component of the disease burden because depressive symptoms occur frequently and can substantially affect quality of life and daily functioning. DelveInsight estimates that approximately 3.6 million prevalent cases of Bipolar Depression were present across the 7MM in 2023, with severe cases representing approximately 75% of the total. Bipolar II Disorder accounted for nearly 60% of diagnosed prevalent cases based on type-specific estimates.
Bipolar Disorder Diagnosis and Treatment Algorithm
There is currently no definitive laboratory test for diagnosing Bipolar Disorder. Diagnosis generally relies on psychiatric evaluation, assessment of the patient’s medical and mood history, symptom patterns, mood charting, and established diagnostic criteria. Because depressive symptoms may predominate and manic or hypomanic episodes can be overlooked, Bipolar Disorder may sometimes be difficult to differentiate from unipolar depression and other psychiatric conditions.
Treatment depends on the phase and severity of the disease and generally aims to achieve symptomatic recovery, stabilize mood, prevent recurrence, and improve overall functioning. Pharmacological options include antipsychotics, mood stabilizers, anticonvulsants, and other agents. Quetiapine and LATUDA (lurasidone) have been used in acute bipolar depressive episodes, while combinations involving lithium, lamotrigine, quetiapine, or lurasidone may also be considered. Cariprazine received US FDA approval for acute bipolar depression in 2019. For refractory cases or bipolar depression with psychotic features, non-pharmacological interventions such as electroconvulsive therapy may also be considered.
Bipolar Disorder Market Players
Key companies operating in the Bipolar Disorder and Bipolar Depression market landscape include:
- Allergan (AbbVie) / Gedeon Richter
- Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)
- Intra-Cellular Therapies
- NeuroRx
- Lundbeck
- Otsuka Pharmaceutical
- Celon Pharma
- COMPASS Pathways
- Xenon Pharmaceuticals
- Autobahn Therapeutics
- Alto Neuroscience
- NRx Pharmaceuticals
- LB Pharmaceuticals
- AbbVie
- And Others
These companies are evaluating marketed products and emerging candidates across different stages of development, with research increasingly emphasizing novel mechanisms, targeted treatment strategies, and therapies designed specifically for bipolar depression.
Bipolar Disorder Epidemiology
The epidemiology section of the Bipolar Disorder market insight report provides historical and forecasted patient population data across the 7MM, including the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The epidemiology assessment includes diagnosed prevalent cases, type-specific cases, severity-specific cases, age-specific cases, and treated cases.
Key Findings:
- DelveInsight estimates that approximately 3.6 million prevalent cases of Bipolar Depression were present across the 7MM in 2023.
- The United States accounted for around 70% of diagnosed prevalent Bipolar Depression cases in the 7MM in 2023.
- Severe cases represented approximately 75% of Bipolar Depression cases in the United States based on severity-specific estimates in 2023.
- The United States represented more than 60% of total treated Bipolar Depression cases across the 7MM in 2023.
- Germany had the highest number of diagnosed prevalent cases among the EU4 and the UK in 2023.
- The epidemiology forecast covers the United States, EU4, the United Kingdom, and Japan through 2036.
Bipolar Disorder Market Outlook
The Bipolar Disorder market trends indicate sustained expansion through 2036, driven by increasing recognition of mental health disorders, improved diagnosis, rising treatment access, and growing pharmaceutical research. The current 2036 market assessment covers the period from 2022 to 2036, with the forecast period extending from 2026 to 2036. The United States remains the dominant market, accounting for around 85% of the 7MM Bipolar Depression market, while Germany represents the leading market among EU4 and the UK.
The market is also expected to benefit from increasing investment in novel therapeutics. By 2036, CAPLYTA (lumateperone) is projected to hold the largest share among currently available Bipolar Depression therapies, while NRX-100 and NRX-101 are anticipated to gain prominent market positions among emerging therapies. Continued research into faster-acting and better-tolerated treatments is expected to further reshape the competitive environment.
Marketed Bipolar Disorder Drugs
- VRAYLAR (cariprazine) – Allergan (AbbVie)/Gedeon Richter
VRAYLAR is an oral atypical antipsychotic containing cariprazine. It is approved in the United States for schizophrenia, bipolar disorder, and Bipolar Depression. In May 2019, the US FDA approved an expanded indication for cariprazine for depressive episodes associated with Bipolar I Disorder in adults. The approval was supported by pivotal clinical trials demonstrating improvement in depressive symptoms compared with placebo.
- LYBALVI (olanzapine and samidorphan) – Alkermes
LYBALVI combines olanzapine with samidorphan in a single tablet. In June 2021, the US FDA approved LYBALVI for adults with Bipolar I Disorder for maintenance monotherapy and for acute manic or mixed episodes, either as monotherapy or alongside lithium or valproate. Its approval was supported by the ENLIGHTEN clinical development program.
- FANAPT (iloperidone) – Vanda Pharmaceuticals
FANAPT is an oral atypical antipsychotic that is approved for schizophrenia and acute manic or mixed episodes associated with Bipolar I Disorder in adults. In April 2024, Vanda Pharmaceuticals reported US FDA approval for the acute treatment of Bipolar I Disorder.
Request the Bipolar Disorder market report for in-depth insights on pipeline and forecast
Emerging Bipolar Disorder Drugs
The Bipolar Disorder market pipeline is evolving with multiple candidates investigating mechanisms beyond conventional approaches. Current development programs are focused on improving depressive symptom control, reducing adverse effects, achieving rapid response, and addressing limitations associated with existing antipsychotic therapies. Key emerging candidates include azetukalner, elunetirom, ABBV-932, NRX-100/NRX-101, and COMP 360, among others.
- Azetukalner – Xenon Pharmaceuticals
Azetukalner is an investigational oral Kv7 potassium channel modulator being developed for Bipolar Depression. The therapy is designed to regulate neuronal hyperexcitability and potentially improve depressive symptoms without inducing mania or producing some adverse effects associated with conventional antipsychotics. In January 2026, the Phase III X-CEED study evaluating azetukalner in Bipolar I or II Depression was reported to be underway.
- Elunetirom (ABX-002) – Autobahn Therapeutics
Elunetirom is an oral, brain-enhanced thyroid hormone beta receptor agonist designed to act on brain regions associated with depression. The candidate is being evaluated as an adjunctive treatment for Bipolar Depression and entered Phase II development. Its mechanism represents a differentiated approach within the emerging treatment landscape.
- ABBV-932 – AbbVie
ABBV-932 is an investigational selective D3 dopamine receptor modulator being developed for Bipolar Disorder and generalized anxiety disorder. The candidate is intended to regulate dopamine pathways involved in mood and anxiety and is being investigated in Phase II development. AbbVie and Gedeon Richter announced a collaboration around the discovery and development of novel neuropsychiatric targets and ABBV-932.
- NRX-100/NRX-101 – NRx Pharmaceuticals
NRX-100/NRX-101 represents a sequential therapeutic approach designed to rapidly stabilize depressive symptoms and suicidal ideation using intravenous ketamine followed by oral NRX-101, a fixed-dose combination involving D-cycloserine and lurasidone. The approach targets NMDA and 5-HT2A pathways and is being investigated as a potential option for patients with significant bipolar depressive symptoms.
- COMP 360 (Psilocybin) – COMPASS Pathways
COMP 360 is an investigational psilocybin-based therapy being evaluated within the broader pipeline of novel approaches for mood disorders. The candidate represents growing interest in mechanismically differentiated treatments that may address persistent limitations associated with conventional pharmacological therapies.
Bipolar Disorder Drugs Uptake
This section evaluates the anticipated uptake of potential Bipolar Disorder therapies expected to enter the market during 2026–2036. Drug adoption is influenced by clinical efficacy, safety and tolerability, mechanism of action, route and frequency of administration, order of market entry, physician acceptance, patient preferences, and the ability of emerging therapies to address existing unmet needs.
The competitive environment is expected to become increasingly dynamic as multiple companies advance candidates through Phase II and Phase III development. In particular, therapies offering faster action, improved tolerability, better control of depressive symptoms, and differentiated mechanisms may gain an advantage over established treatments. DelveInsight’s assessment also considers clinical trial outcomes, market competition, probability of success, and addressable patient populations when evaluating potential uptake.
Conclusion
The Bipolar Disorder market is expected to undergo substantial transformation through 2036 as diagnosis improves, mental health awareness increases, and innovative treatment strategies progress through clinical development. Existing therapies such as cariprazine and other antipsychotic approaches continue to play an important role, while emerging candidates are seeking to address persistent challenges in depressive symptom management, tolerability, rapid response, and long-term disease control. The strong clinical pipeline, increasing healthcare investment, and expanding treatment options are expected to create new opportunities across the 7MM. As novel mechanisms progress toward potential commercialization, the treatment landscape could become more competitive and patient-focused, supporting improved therapeutic outcomes and continued market expansion.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: info@delveinsight.com
